Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

Q2 2026 revenue doubled year-over-year, with strong U.S. growth and UAE market entry

13 August 2026 · By · Wire by Fusion42

Published

13 August 2026

Topic

operational-macro

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at tradingview.com →

◆ Verified

Fusion42 · 13 August 2026 · Fusion42 review

Acarix doubled its Q2 2026 revenue year-over-year with strong growth in the U.S. and regulatory approval enabling entry into the UAE market. Financial performance also improved with high gross margins and reduced operating expenses.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ ◆ The Wire takeaway

You have new market access in the UAE and proven U.S. growth, turning these regions into concrete sales opportunities. This entry means you need to prioritise regulatory readiness and local partnerships now before competitors gain ground.

◆ Coverage

1 source · 13 Aug 2026

◆ Related on Wire

◆ Topics

Medtechrevenue-growthmarket-entryUS-expansionUAE-approvalmedtech